期刊
ORGANIC PROCESS RESEARCH & DEVELOPMENT
卷 24, 期 11, 页码 2549-2564出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.oprd.0c00229
关键词
continuous processing; flow chemistry; tetrahydroisoquinoline; mevidalen; process development; co-crystal; D1 PAM; LY3154207
The evolution from early medicinal chemistry to large-scale production of the chemical synthesis of Lilly D1-positive allosteric modulator (PAM) mevidalen (LY3154207) and its hydroxybenzoate co-crystal is outlined. The issues and steps taken to resolve them are outlined across several generations of synthesis, including unexpected issues that arose during cryogenic addition of MeLi to a key imine intermediate and the use of flow chemistry to enable large-scale production. Ultimately, a process that was used to deliver >100 kg of API to support ongoing clinical trials is described.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据